Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Anti-Cancer Drugs

• Publication date

  2006-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.CAD.0000182748.47353.51PMID 16317284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy for urological malignancies.

  2004cited by this paper
• Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon α, β and interleukin-2

  2004cited by this paper
• Immunomodulation in a Treatment Program Including Pre- and Post-Operative Interleukin-2 and Chemotherapy for Childhood Osteosarcoma

  2003cited by this paper
• Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with multikine.

  2003cited by this paper
• IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

  2003cited by this paper
• Immunotherapy and biological modifiers for the treatment of malignant brain tumors.

  2003cited by this paper
• Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study.

  2003cited by this paper
• Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2.

  2003cited by this paper
• Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

  2003cited by this paper
• Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.

  2003cited by this paper
• Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus Interleukin-2

  2003cited by this paper
• Immunology and immunotherapy of colorectal cancer.

  2003cited by this paper
• Ultra-Low-Dose Interleukin-2 in Unresectable Hepatocellular Carcinoma

  2002cited by this paper
• A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.

  2002cited by this paper
• Safety and Efficacy of High-Dose Interleukin-2 Therapy in Patients With Brain Metastases

  2002cited by this paper
• Management of advanced pancreatic cancer: staging laparoscopy and immunochemotherapy--a new treatment strategy.

  2002cited by this paper
• Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.

  2002cited by this paper
• Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.

  2002cited by this paper
• [Hepatic arterial infusion of IL-2 and chemotherapy for unresectable liver metastasis from colorectal cancer].

  2002cited by this paper
• Locoregional immunochemotherapy in hepatocellular carcinoma.

  2002cited by this paper
• Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.

  2002cited by this paper
• Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.

  2002cited by this paper
• The role of new agents in the treatment of non-small cell lung cancer.

  2002cited by this paper
• Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?

  2002cited by this paper
• Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition?

  2002cited by this paper
• Phase II Trial of Systemic Recombinant Interleukin-2 in the Treatment of Refractory Nasopharyngeal Carcinoma

  2001cited by this paper
• Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.

  2001cited by this paper
• Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer.

  2001cited by this paper
• Controlled Local Delivery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain Tumors and Liver Tumors

  2001cited by this paper
• A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.

  2001cited by this paper
• Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2.

  2001cited by this paper
• Progress Report on the Palliative Therapy of 100 Patients with Neoplastic Effusions by Intracavitary Low-Dose Interleukin-2

  2001cited by this paper
• A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer.

  2001cited by this paper
• Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.

  2001cited by this paper
• Science, medicine, and the future: Cellular immunotherapy for cancer.

  2001cited by this paper
• [Multidisciplinary treatment for liver metastasis using cytokines].

  2001cited by this paper
• Effect of octreotide on proliferation of in vitro cultured thyroid medullary carcinoma cells.

  2001cited by this paper
• Neoadiuvant Treatment With Intravesical Interleukin-2 for Recurrent Superficial Transitional Bladder Carcinoma Ta-T1/G1-2

  2001cited by this paper
• Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial.

  2001cited by this paper
• Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission

  2001cited by this paper
• The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.

  2001cited by this paper
• Pilot study of immunotherapy with interleukin-2 after autologous stem cell transplantation in advanced breast cancers.

  2000cited by this paper
• Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer.

  2000cited by this paper
• Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.

  2000cited by this paper
• Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

  2000cited by this paper
• Long-term survival in small cell lung cancer patients is correlated with high interleukin-2 secretion at diagnosis

  2000cited by this paper
• Interleukin-2 in the treatment of hematologic malignancies.

  2000cited by this paper
• A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.

  2000cited by this paper
• Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.

  2000cited by this paper
• High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II study

  2000cited by this paper
• Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer

  2000cited by this paper
• Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival

  2000cited by this paper
• Treatment with interleukin-2 (IL-2) and interferon (IFNalpha 2b) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse

  1999cited by this paper
• Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: results of a pilot study.

  1999cited by this paper
• Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?

  1999cited by this paper
• Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer.

  1999cited by this paper
• Combined Surgical and Immunotherapeutic Treatment of Patients with Fourth Stage Colon Cancer

  1999cited by this paper
• Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patients.

  1999cited by this paper
• A pilot study of interleukin‐2 for adult patients with acute myelogenous leukemia in first complete remission

  1999cited by this paper
• Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2).

  1999cited by this paper
• Immunotherapy with interleukin-2 and α-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer

  1999cited by this paper
• A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586).

  1999cited by this paper
• Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma

  1998cited by this paper
• Analysis of Interleukin-2/Interleukin-2 Receptor System in Advanced Non-Small-Cell Lung Cancer

  1998cited by this paper
• [Clinical evaluation of intermittent hepatic arterial infusion therapy for metastatic liver tumor of gastric and colorectal cancer].

  1998cited by this paper
• Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha

  1998cited by this paper
• Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma

  1998cited by this paper
• Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients

  1998cited by this paper
• Pancreatic resection for pancreatic carcinoma combined with neo- and adjuvant locoregional targeting immuno-chemotherapy--a prospective randomized study.

  1998cited by this paper
• A prospective randomized study using adjuvant locoregional chemoimmunotherapy in combination with surgery for pancreatic carcinoma.

  1998cited by this paper
• A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study.

  1998cited by this paper
• Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients.

  1998cited by this paper
• Immunotherapy in lung cancer.

  1998cited by this paper
• rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: response and enhancement of further chemosensitivity.

  1998cited by this paper
• Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC.

  1998cited by this paper
• Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

  1998cited by this paper
• Combined Epirubicin and Interleukin-2 Regimen in the Treatment of Malignant Mesothelioma: A Multicenter Phase II Study of the Italian Group on Rare Tumors

  1998cited by this paper
• Intrapleural administration of recombinant interleukin-2 in non-small cell lung cancer with neoplastic pleural effusion.

  1997cited by this paper
• Decrease of interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer.

  1997cited by this paper
• Clinical and Immunologic Effects of Monoclonal Antibody CC49 and Interleukin-2 in Patients with Metastatic Colorectal Cancer

  1997cited by this paper
• Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates

  1997cited by this paper
• Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion.

  1997cited by this paper
• Natural history and therapy of metastatic renal cell carcinoma

  1997cited by this paper
• Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

  1997cited by this paper
• Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL‐2) and alpha‐interferon (A‐IFN) for stage D3 prostate carcinoma failing second‐line hormonal treatment

  1996cited by this paper
• Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

  1996cited by this paper
• A randomized trial of adoptive immunotherapy with tumor‐infiltrating lymphocytes and interleukin‐2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung cancer

  1996cited by this paper
• Locoregional chemotherapy versus locoregional combined immuno-chemotherapy for patients with advanced metastatic liver disease of colorectal origin: a prospective randomized study.

  1996cited by this paper
• Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin‐C) regimen: A phase II study

  1996cited by this paper
• A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study

  1995cited by this paper
• Long-term Subcutaneous Recombinant Interleukin-2 as Maintenance Therapy: Biological Effects and Clinical Implications

  1995cited by this paper
• Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. A pilot study.

  1995cited by this paper
• TREATMENT OF 23 PATIENTS WITH ADVANCED GASTRIC CANCER BY INTRAVENOUSLY TRANSFER OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES COMBINED WITH rIL-2

  1995cited by this paper
• Adjuvant Chemoimmunotherapy for Hepatocellular Carcinoma Patients: Adriamycin, Interleukin‐2, and Lymphokine‐Activated Killer Cells Versus

  1995cited by this paper
• A Phase II Trial of Interleukin‐2 and Interferon‐α in the Treatment of Metastatic Colorectal Carcinoma

  1995cited by this paper
• Combined Transarterial Targeting Locoregional Immunotherapy-Chemotherapy for Patients with Unresectable Hepatocellular Carcinoma: A New Alternative for an Old Problem

  1995cited by this paper
• Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer.

  1995cited by this paper
• Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

  1995cited by this paper
• A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.

  1995cited by this paper
• Selective suppression of cytokine secretion in patients with small-cell lung cancer.

  1995cited by this paper

• Inflammatory Cytokine Levels in Patients with Sporadic Amyotrophic Lateral Sclerosis

  2022cites this paper
• Melatonin and breast cancer: Evidences from preclinical and human studies.

  2018cites this paper
• Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.

  2018cites this paper
• Ovarian cancer and inflammation. Part 1. Pro-inflammatory cytokines.

  2018cites this paper
• Proximal signaling responses in peripheral T cells from colorectal cancer patients are affected by high concentrations of circulating prostaglandin E2.

  2017cites this paper
• Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?

  2017cites this paper
• The Diagnostic Roles of Cytokines in Hepatobiliary Cancers

  2017cites this paper
• Genetic variants in gastric cancer: Risks and clinical implications.

  2017cites this paper
• PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques

  2017cites this paper
• Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon

  2016cites this paper
• Immunotherapy for Head and Neck Squamous Cell Carcinoma

  2016cites this paper
• Immunotherapy in head and neck cancer: Harnessing profit on a system disruption.

  2016cites this paper
• Immunotherapy for head and neck squamous cell carcinoma.

  2015cites this paper
• In vivo model for mastocytosis: A comparative review.

  2015cites this paper
• Overcoming tumor-mediated immunosuppression.

  2014cites this paper
• Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

  2014cites this paper
• Increased proinflammatory cytokines in sera of patients with multifocal motor neuropathy.

  2014cites this paper
• Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs.

  2013cites this paper
• Gastric Cancer Immunotherapy: An Overview

  2013cites this paper
• Interleukin-2 Receptor Expression in Canine Cutaneous Mast Cell Tumors

  2013cites this paper
• A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.

  2013cites this paper
• Melatonin: a pleiotropic molecule of natural origin. Evaluation of the different therapeutic activities in animal models and / or human patients and a study of the metabolic-biochemical pathways related to them.

  2013cites this paper
• Immunotherapy for metastatic colorectal cancer: Present status and new options

  2012influential citation
• Novel cellular and molecular approaches to stratification and treatment of colorectal cancer.

  2012cites this paper
• Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

  2012cites this paper
• Growth Factors and their receptors in cancer metastases.

  2011cites this paper
• Melatonin, immune function and cancer.

  2011cites this paper
• Alternative treatment of chemoresistant, recurrent or advanced ovarian cancer. Part I

  2011cites this paper
• UNIVERSITÁ DEGLI STUDI DI MILANO FACOLTÁ DI MEDICINA E CHIRURGIA

  2010cites this paper
• Dietary Phenethyl Isothiocyanate Alters Gene Expression in Human Breast Cancer Cells

  2010cites this paper
• Serum cytokine concentrations, flavonol intake and colorectal adenoma recurrence in the Polyp Prevention Trial

  2010cites this paper
• Activation of innate immunity to reduce lung metastases in breast cancer

  2010cites this paper
• A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer

  2010cites this paper
• An Agent-Based Model of Solid Tumor Progression

  2009influential citation
• Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.

  2009cites this paper
• Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact

  2009cites this paper
• A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis

  2009cites this paper
• Immunotherapy of Head and Neck Cancer: Current and Future Considerations

  2009cites this paper
• Modeling of Solid Tumor Progression Thresholds using a Complex Adaptive System Approach

  2009cites this paper
• Local therapy of cancer with free IL-2

  2008cites this paper
• Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma.

  2008cites this paper
• Anti-Cancer Drugs 2008 Author Index to Volume 19.

  2008cites this paper
• Rebuilding immunity in cancer patients.

  2008cites this paper
• 123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma

  2008cites this paper
• Competition Lymphocytes in the Absence of APC TResponses by IL-2-and Antigen-Stimulated In Vivo Suppression of Naive CD 4 T Cell

  2008cites this paper
• CD4+ T‐regulatory cells: toward therapy for human diseases

  2008cites this paper
• In Vivo Suppression of Naive CD4 T Cell Responses by IL-2- and Antigen-Stimulated T Lymphocytes in the Absence of APC Competition1

  2008cites this paper
• Streptavidin-cytokine fusion proteins for use as adjuvants in cancer vaccines

  2008cites this paper
• (123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma.

  2008cites this paper
• Role of Cytokines

  2008cites this paper
• TNF and manipulation of the tumor cell-stromal interface: "ways to make chemotherapy effective".

  2008cites this paper
• Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer.

  2007cites this paper
• Four-Modality Therapy in Malignant Pleural Mesothelioma: A Phase II Study

  2007cites this paper
• Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.

  2007cites this paper
• A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.

  2007influential citation
• The evolutionary transition from subsocial to eusocial behaviour in Dictyoptera: phylogenetic evidence for modification of the "shift-in-dependent-care" hypothesis with a new subsocial cockroach.

  2007cites this paper
• Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors.

  2007cites this paper
• Cytotoxic drugs sensitize tumor cells to immune cell-mediated killing by interleukin-2 activated peripheral blood leukocytes

  2007cites this paper
• Interleukin (IL)-12 receptor beta1 codon 378 G homozygote and allele, but not IL-1 (beta-511 promoter, 3953 exon 5, receptor antagonist), IL-2 114, IL-4-590 intron 3, IL-8 3'-UTR 2767, and IL-18 105, are associated with higher susceptibility to leiomyoma.

  2007cites this paper
• Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer

  2007cites this paper
• Low-dose Interleukin-2 Administered Pre-operatively to Patients with Gastric Cancer Activates Peripheral and Peritumoral Lymphocytes But Does Not Affect Prognosis

  2007cites this paper
• Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.

  2006cites this paper